Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service SettingNamritha Patrao, Ranjan Rajendram, Robin Hamilton et al.|American Journal of Ophthalmology|2016Cited by 86
Identification of time point to best define ‘sub-optimal response’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life dataIrini Chatziralli, Sobha Sivaprasad, Martina Santarelli et al.|Eye|2017Cited by 24
Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedemaLuke Nicholson, Sobha Sivaprasad, Namritha Patrao et al.|Eye|2017Cited by 4
Impact of vitrectomy on outcomes of treatment for diabetic macular oedema with intravitreal ranibizumabSheelah Antao, Ranjan Rajendram, James Bainbridge et al.|UCL Discovery (University College London)|2016Cited by 0